Joint Formulary & PAD

Formulary Search

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Search

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A-Z of Drugs

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Epilepsy (Oxcarbazepine - Epilepsy)

Records returned : 39 (on 29 May 2025 at 13:06:21). Return to search results for ' Epilepsy '.

Show Icon and Status Keys

Drug
Indication
Status
Restrictions/Comments
Formulary Status
Links
Indication :
Status :
Blue
Formulations :
  • Oral suspension
  • Tablets
Restrictions / Comments:

 
Links :
SPC
Indication :
Status :
Blue
Formulations :
  • Oral solution
  • Tablets
Restrictions / Comments:

Important
Reserved for patients who remain uncontrolled or intolerant to all other adjuntive anti-epileptics. Only for use when levetiracetam has not been effective or tolerated.

To be initiated by a specialist.

 
Links :
SPC
R
Indication :
Status :
Red
Formulations :
  • Injection
Restrictions / Comments:

Important
Reserved for patients who remain uncontrolled or intolerant to all other adjuntive anti-epileptics. Only for use when levetiracetam has not been effective or tolerated.
 
Links :
SPC
Indication :
Status :
Blue
Formulations :
  • Modified release tablets
  • Oral suspension
  • Suppositories
  • Tablets
Restrictions / Comments:

Important
Ensure that the patient is maintained on a specific manufacturer’s product
 
Links :
SPC
Indication :
Status :
Blue
Formulations :
  • Oral suspension
  • Tablets
Restrictions / Comments:

 
Links :
SPC
CD
Indication :
Status :
Blue
Formulations :
  • Oral solution
  • Tablets
Restrictions / Comments:

 
Links :
SPC
CD
Indication :
Status :
Blue
Formulations :
  • Capsules
  • Oral solution
Restrictions / Comments:

Important
For absence, atypical and myoclonic seizures
 
Links :
SPC
Indication :
Status :
Blue
Formulations :
  • Capsules
  • Oral solution
  • Tablets
Restrictions / Comments:

 
Links :
SPC
CD
Indication :
Status :
Blue
Formulations :
  • Oral solution
  • Tablets
Restrictions / Comments:

 
Links :
SPC
Indication :
Status :
Red
Formulations :
  • Infusion
Restrictions / Comments:

 
Links :
SPC
Indication :
Status :
Blue
Formulations :
  • Dispersible tablets
  • Tablets
Restrictions / Comments:

 
Links :
SPC
Indication :
Status :
Blue
Formulations :
  • Oral solution
  • Tablets
Restrictions / Comments:

 
Links :
SPC
Indication :
Status :
Blue
Formulations :
  • Granules
Restrictions / Comments:

 
Links :
SPC
Indication :
Status :
Red
Formulations :
  • Infusion
Restrictions / Comments:

 
Links :
SPC
Indication :
Status :
Blue
Formulations :
  • Tablets
Restrictions / Comments:

Important
Requires specialist initiation and supply for at least 12 weeks prior to a transfer of care to primary care prescribers
 
Links :
SPC
Indication :
Status :
Blue
Formulations :
  • Elixir
  • Tablets
Restrictions / Comments:

Important
Ensure that the patient is maintained on a specific manufacturer’s product
 
Links :
SPC
CD
Indication :
Status :
Blue
Formulations :
  • Liquid
Restrictions / Comments:

Important
Ensure that the patient is maintained on a specific manufacturer’s product
Unlicensed phenobarbital liquid 50mg/5ml (sugar and alcohol free) for paediatric use (as recommended by the RCPCH and NPPG).
 
Links :
SPC
CD
Un
Indication :
Status :
Blue
Formulations :
  • Capsules
  • Oral suspension
  • Tablets
Restrictions / Comments:

Important
Ensure that the patient is maintained on a specific manufacturer’s product. Phenytoin sodium is NOT EQUIVALENT to Phenytoin base (suspension). When switching between products, 100mg of phenytoin sodium is approximately equivalent to 92mg of phenytoin base.
 
Links :
SPC
Indication :
Status :
Blue
Formulations :
  • Capsules
  • Oral solution
Restrictions / Comments:

Important
Capsules are more cost effective than tablets
 
Links :
SPC
CD
Indication :
Status :
Blue
Formulations :
  • Tablets
Restrictions / Comments:

Important
Prescribe by brand - ensure patient is maintained on a specific product.
 
Links :
SPC
Indication :
Status :
Blue
Formulations :
  • Crushable tablets
  • Gastro-resistant tablets
  • Modified release tablets
  • Oral solution
  • Tablets
Restrictions / Comments:

 
Links :
SPC
Indication :
Status :
Blue
Formulations :
  • Capsules (slow release)
  • Granules (slow release)
Restrictions / Comments:

 
Links :
SPC
Indication :
Status :
Red
Formulations :
  • Injection
Restrictions / Comments:

 
Links :
SPC
Indication :
Status :
Blue
Formulations :
  • Capsules
  • Oral suspension
  • Tablets
Restrictions / Comments:

Important
Pregnancy Prevention Plan required for females of childbearing potential.
Capsules (Sprinkle) reserved for use in patients who cannot swallow tablets. Liquid reserved for patients who cannot swallow tablets or capsules
 
Links :
SPC
Indication :
Status :
Blue
Formulations :
  • Sachets (powder)
  • Tablets
Restrictions / Comments:

Important
Specialist initiation before transfer of prescribing to primary care
 
Links :
SPC
Indication :
Status :
Non Formulary
Formulations :
  • Soluble tablets
Restrictions / Comments:

 
Links :
SPC
NFD1
Indication :
Status :
Blue
Formulations :
  • Capsules
Restrictions / Comments:

 
Links :
SPC
Indication :
Status :
Blue
Formulations :
  • Oral suspension
Restrictions / Comments:

Important
Zonisamide 20mg/ml is the only licensed oral suspension available.
 
Links :
SPC
Indication :
Status :
Amber
Formulations :
  • Tablets
Restrictions / Comments:

Important
Only when 1st-line and 1st-line adjunctive agents have been unsuccessful
 
Links :
SPC
R
Indication :
Status :
Amber
Formulations :
  • Tablets
Restrictions / Comments:

Important
SASH - restricted to paediatrics only. RSCH - only initiate on recommendation from a tertiary referral centre.
 
Links :
SPC
R
Indication :
Status :
Amber
Formulations :
  • Oral suspension
Restrictions / Comments:

Important
RSCH - only initiate on recommendation from a tertiary referral centre.
 
Links :
SPC
R
Indication :
Status :
Amber
Formulations :
  • Capsules (slow release)
  • Granules (slow release)
Restrictions / Comments:

Important
Pregnancy Prevention Programme required. See MHRA advice
 
Links :
SPC
Indication :
Status :
Amber
Formulations :
  • Crushable tablets
  • Gastro-resistant tablets
  • Modified release tablets
  • Oral solution
  • Tablets
Restrictions / Comments:

Important
Pregnancy Prevention Programme required. See MHRA advice
 
Links :
SPC
Indication :
Status :
Red
Formulations :
  • Injection
Restrictions / Comments:

Important
Pregnancy Prevention Programme required. See MHRA advice
 
Links :
SPC
Indication :
Status :
Red
Formulations :
  • Oral solution
Restrictions / Comments:

Important
Specialist centres only (including ongoing supply)
 
Links :
SPC
CD
Indication :
Status :
Red
Formulations :
  • Tablets
Restrictions / Comments:

Important
For initiation by tertiary centres only
 
Links :
SPC
Indication :
Status :
Red
Formulations :
  • Capsules
Restrictions / Comments:

Important
Initiation and adjustment by consultant paediatricians only.
 
Links :
SPC
Indication :
Status :
Non Formulary
Formulations :
  • Oral suspension
Restrictions / Comments:

 
Links :
SPC
NFD2
Indication :
Status :
Non Formulary
Restrictions / Comments:

 
Links :
SPC
NFD1